BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported third quarter 2025 financial results and provided a business update.
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Seeking Alpha / 3 hours from now 1 Views
Comments